Abeona Therapeutics (ABEO) Amortization of Deferred Charges (2020 - 2026)

Abeona Therapeutics' Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $179000.0 for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 36.3% year-over-year to $179000.0 in Q1 2026; TTM through Mar 2026 was $912000.0, a 4.1% decrease from a year earlier, with the FY2025 full-year figure at $1.0 million, up 12.29% from the prior year.
• Amortization of Deferred Charges fell to $179000.0 in Q1 2026 per ABEO's latest filing, from $229000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $597000.0 in Q2 2022 and bottomed at $179000.0 in Q1 2026.
• The 5-year median for Amortization of Deferred Charges is $233000.0 (2024), against an average of $264117.6.
• Across the five-year window, Amortization of Deferred Charges soared 117.09% in 2022 and plunged 62.65% in 2023, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $280000.0 in 2022, then decreased by 17.86% to $230000.0 in 2023, then grew by 3.04% to $237000.0 in 2024, then fell by 3.38% to $229000.0 in 2025, then dropped by 21.83% to $179000.0 in 2026.
• Per Business Quant, the three latest ABEO Amortization of Deferred Charges figures stand at $179000.0 (Q1 2026), $229000.0 (Q4 2025), and $280000.0 (Q3 2025).